豆丁微信公众号
君，已阅读到文档的结尾了呢~~
2013-2014美国处方量TOP100_药品
扫扫二维码，随身浏览文档
手机或平板扫扫即可继续访问
美国处方量TOP100_药品
举报该文档为侵权文档。
举报该文档含有违规或不良信息。
反馈该文档无法正常浏览。
举报该文档为重复文档。
推荐理由：
将文档分享至：
分享完整地址
文档地址：
粘贴到BBS或博客
flash地址：
支持嵌入FLASH地址的网站使用
html代码：
&embed src='http://www.docin.com/DocinViewer--144.swf' width='100%' height='600' type=application/x-shockwave-flash ALLOWFULLSCREEN='true' ALLOWSCRIPTACCESS='always'&&/embed&
450px*300px480px*400px650px*490px
支持嵌入HTML代码的网站使用
您的内容已经提交成功
您所提交的内容需要审核后才能发布，请您等待！
3秒自动关闭窗口GEL (loteprednol etabonate ophthalmic gel) 0.5%
& && & && && && && && && &&& &&
Indication
GEL (loteprednol etabonate ophthalmic gel)
is used to treat inflammation and pain following eye surgery.
Important Safety Information
LOTEMAX GEL should not be used if you have an infection in your eye.
Before using LOTEMAX GEL, turn bottle upside down and shake once to fill the bottle tip. To avoid contamination, do not let dropper touch any surface.
Do not wear contact lenses when using LOTEMAX GEL.
Contact your doctor if pain develops or if redness, itching or inflammation becomes aggravated.
If you use LOTEMAX GEL for longer than 10 days, your doctor may monitor pressure in your eye. Use of medications such as LOTEMAX GEL may result in cataract formation, or may delay healing after cataract surgery.
The most common side effects in clinical studies were eye inflammation, eye pain and foreign body sensation.
for full Prescribing Information about LOTEMAX GEL.
You are encouraged to report negative side effects of prescription drugs to the FDA.
or call 1-800-FDA-1088
LGX.0146.USA.17
UNITED STATES
--Please Select--
?sterreich
Canada (English)
Canada (Fran?ais)
?eská republika
Deutschland
Netherlands
New Zealand
Philippines
Россия
South Africa
United Kingdom
United StatesHide glossary
Study record managers: refer to the
if submitting registration or results information.
Search for terms
Study Record Detail
Saved Studies
Save this study
You have reached the maximum number of saved studies (100).
Please remove one or more studies before adding more.
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
for details.
ClinicalTrials.gov Identifier: NCT
Recruitment Status :
(Per Sponsor)
First Posted : January 7, 2014
: March 18, 2015
Study Details
Brief Summary:
A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel 0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in subjects with dry eye.
Dry Eye Disease
Drug: Loteprednol etabonate
Drug: Artificial Tears
Drug: Restasis
Study Type :
Interventional
&(Clinical Trial)
Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Single (Investigator)
Primary Purpose:
January 2014
Estimated :
February 2016
Estimated :
Resource links provided by the National Library of Medicine
available for:
Active Comparator: Loteprednol etabonate + Restasis
Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
Drug: Loteprednol etabonate
Drug: Restasis
Placebo Comparator: Artificial Tears + Restasis
Artificial Tears, BID 30 days Restasis, BID 45 days
Drug: Artificial Tears
Drug: Restasis
Primary Outcome Measures :
Fluorescein corneal staining scores [&Time&Frame:&60 Days&]
Secondary Outcome Measures :
Lissamine green conjunctival staining [&Time&Frame:&60 Days&]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information,
Ages Eligible for Study: &
21 Years to 80 Years & (Adult, Older Adult)
Sexes Eligible for Study: &
Accepts Healthy Volunteers: &
Inclusion Criteria:
Provide written informed consent prior to any study-related procedures and provide Health Insurance Portability and Accountability Act (HIPAA) authorization.
Are between the ages of 21 and 80 inclusive.
Have not worn contact lenses for at least 1 month prior to the study and agrees not to wear contact lenses during the study.
Have been on stable oral medications for 1 month prior to the study.
Are in generally good and stable overall health.
Are a woman of child bearing potential (WOCBP) who is not pregnant or lactating and not sexually active (i.e. abstinent) at Visit 1 and willing to remain so through Visit 4. Alternatively, a WOCBP who is not abstinent must have been using an acceptable method of birth control for at least 4 weeks prior to Visit 1 and throughout the study.
Are women who have undergone one of the following sterilization procedures at least 1 month prior to Visit 1:
Bilateral tubal ligation
Hysterectomy
Hysterectomy with unilateral or bilateral oophorectomy.
Bilateral oophorectomy
Are likely to comply with the eye drop regime, study guidelines, and study visits.
Exclusion Criteria:
Have a history of Stevens-Johnson Syndrome or ocular pemphigoid.
Have had punctual plugs or punctual cautery 3 months prior to Visit 1/Screening and Baseline Visit and throughout the study.
Have had intra-ocular surgery within 6 months prior to the Visit 1/Screening and Baseline Visit.
Have a history of liver disease.
Be pregnant or lactating.
Have severe clinical vitamin deficiencies or a history of vitamin overdose.
Have a highly variable vitamin intake.
Wear contact lenses.
Have unstable use of systemic or topical medications known to create dry eye.
Have corneal pathology, which could, of itself, cause an ocular surface disorder.
Have used glaucoma medications, topical or oral within 30 days of Visit 1/Screening and Baseline Visit.
Have unstable diabetes mellitus.
Have an allergy or sensitivity to Lotemax® Gel, Restasis®, or non-preservative artificial tears.
Have used topical steroids or Restasis® within 1 month prior to the Screening and Baseline Visit and throughout the study, except the study medication provided per the protocol.
Have a condition for which steroid use would be contraindicated (e.g. viral infection).
Use other topical ocular agents other than tear replacements within 1 week prior to the Screening and Baseline Visit and throughout the study.
Have been exposed to an investigational drug within the preceding 30 days.
In the opinion of the investigator or study coordinator, be unwilling or unable to comply with the study protocol or unable to successfully instill eye drops.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT
Cincinnati Eye Institute
Edgewood, Kentucky, United States, 41017
Edward Holland, MD
Responsible Party:
Edward Holland, MD, Sponsor-Investigator, Holprovision
ClinicalTrials.gov Identifier:
Other Study ID Numbers:
CEI.HER-002
First Posted:
January 7, 2014
Last Update Posted:
March 18, 2015
Last Verified:
March 2015
Keywords provided by Edward Holland, MD, Holprovision:
Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Lubricant Eye Drops
Loteprednol Etabonate
Cyclosporins
Cyclosporine
Ophthalmic Solutions
Pharmaceutical Solutions
Anti-Allergic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors